Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in thee countries across Africa, Centra Asia and the Middle East.
1 Min Read
Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, Centra Asia and the Middle East.
Semalutide improves glycemic control in adults. The product patent expires in most these markets in March 2026. Ajanta Pharma is planning to commercialise it after receiving regulatory approvals, which are expected in late 2026 or early 2027.
The company’s managing director Yogesh Agarwal said GLP-1 therapies have witnessed rapid global acceptance and have emerged as blockbuster products across the world. “We are excited to partner with Biocon for semaglutide and take this important therapy to the markets where Ajanta has strong on-ground presence and deep reach,” he said.
Shares of Ajanta Pharma are trading 5.1% higher on Wednesday at ₹2,804.8. The stock has surged over 11% in the last one month, trimming its year-to-date losses down to 6.5%. This will be the first negative year for the stock after 2022, having gained 41% last year and 72% in 2023.
Also Read: VIP Industries promoter Piramal family completes stake sale to Multiples after large deal
